NP / PA
Beverly M Gaines, MD & Associates, PSC
Beverly M Gaines, MD & Associates, PSC was paid $3.64M by Medicaid between Jan 2018 and Jan 2024, across 90 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 12% of everything it billed.
33Billing provider infoBEVERLY M GAINES, MD & ASSOCIATES, PSC
LOUISVILLE, KY 40204
LOUISVILLE, KY 40204
33aNPI1265512719assigned 10/17/2006
33bProvider typeMedical Physician Assistant
28Total paid$3.64M
24GClaims151,435
24DCodes billed90
24AFirst – last monthJan 2018 – Jan 2024
Compared with peers
Next to other Medical Physician Assistant providers in Kentucky
Rank by total paid#6 of 45
Median peer was paid$258K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,232 | $665K | |
| 2019 | 31,298 | $885K | |
| 2020 | 27,194 | $674K | |
| 2021 | 24,977 | $599K | |
| 2022 | 19,083 | $434K | |
| 2023 | 15,299 | $353K | |
| 2024incomplete | 1,352 | $30K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 10,089 | 9,196 | $455K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.6% | 9,668 | 8,978 | $350K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 9.4% | 8,751 | 8,013 | $341K |
| 99173 | 9.0% | 7,697 | 7,433 | $329K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 8.3% | 4,075 | 3,945 | $304K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 8.0% | 3,819 | 3,670 | $291K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 6.9% | 3,508 | 3,345 | $252K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 6.3% | 2,825 | 2,727 | $229K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.4% | 1,391 | 1,332 | $162K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.3% | 2,458 | 2,333 | $121K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.1% | 12,932 | 12,263 | $112K |
| 99408 | 3.0% | 4,574 | 4,442 | $109K |
78 more codes
| 92552 | 2.4% | 7,805 | $89K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 2,327 | $59K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.5% | 3,661 | $56K |
| 87070 | 1.4% | 5,196 | $51K | |
| 99429 | 1.2% | 637 | $42K | |
| 87634 | 1.1% | 534 | $40K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.0% | 122 | $38K |
| D1206 | Topical application of fluoride varnish | <1% | 1,599 | $19K |
| 81003 | <1% | 8,820 | $18K | |
| 36416 | <1% | 12,922 | $17K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 891 | $14K |
| 99188 | <1% | 757 | $11K | |
| 99484 | <1% | 235 | $8K | |
| 95117 | <1% | 675 | $8K | |
| 99174 | <1% | 806 | $8K | |
| 90648 | <1% | 1,825 | $8K | |
| 90670 | <1% | 2,696 | $7K | |
| 0001A | <1% | 184 | $7K | |
| 83655 | <1% | 538 | $7K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 402 | $6K |
| 90620 | <1% | 387 | $5K | |
| 90651 | <1% | 1,190 | $5K | |
| 90723 | <1% | 1,366 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 123 | $5K |
| 90686 | <1% | 2,306 | $4K | |
| 0002A | <1% | 111 | $4K | |
| 97803 | <1% | 911 | $4K | |
| 92567 | <1% | 249 | $4K | |
| 87581 | <1% | 122 | $3K | |
| 90633 | <1% | 1,054 | $3K | |
| 90734 | <1% | 916 | $3K | |
| 90681 | <1% | 638 | $3K | |
| 80305 | <1% | 139 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 246 | $2K |
| 96127 | <1% | 473 | $2K | |
| 0011A | <1% | 43 | $2K | |
| 0071A | <1% | 41 | $2K | |
| 90710 | <1% | 795 | $2K | |
| 0012A | <1% | 37 | $1K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 33 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 133 | $1K |
| 90715 | <1% | 294 | $1K | |
| 90688 | <1% | 105 | $1K | |
| 94060 | <1% | 34 | $997.86 | |
| 99460 | <1% | 13 | $981.68 | |
| 87807 | <1% | 62 | $927.64 | |
| 95115 | <1% | 85 | $872.94 | |
| 90700 | <1% | 81 | $607.29 | |
| 0072A | <1% | 12 | $492.00 | |
| 82977 | <1% | 30 | $245.78 | |
| 82150 | <1% | 30 | $221.19 | |
| 86308 | <1% | 29 | $215.74 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16 | $196.35 |
| 84550 | <1% | 30 | $154.24 | |
| 84460 | <1% | 30 | $154.18 | |
| 84075 | <1% | 30 | $150.65 | |
| 84450 | <1% | 30 | $150.54 | |
| 82310 | <1% | 30 | $150.08 | |
| 82565 | <1% | 30 | $149.04 | |
| 82040 | <1% | 30 | $143.82 | |
| 82247 | <1% | 28 | $141.07 | |
| 90696 | <1% | 93 | $128.94 | |
| 82947 | <1% | 30 | $116.14 | |
| 84520 | <1% | 30 | $114.95 | |
| 84155 | <1% | 30 | $106.67 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 202 | $84.93 |
| 80051 | <1% | 13 | $68.64 | |
| 94760 | <1% | 146 | $43.28 | |
| 3008F | <1% | 8,491 | $31.31 | |
| 2014F | <1% | 4,491 | $3.82 | |
| 90697 | <1% | 439 | $0.68 | |
| 90647 | <1% | 97 | $0.18 | |
| 91300 | <1% | 369 | $0.13 | |
| 90707 | <1% | 15 | $0.02 | |
| 90716 | <1% | 15 | $0.02 | |
| 90749 | 0% | 45 | $0.00 | |
| 91301 | 0% | 83 | $0.00 | |
| 91307 | 0% | 85 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGAINES, BEVERLY (PRESIDENT & CEO)